Imago BioSciences, Inc. (IMGO)

NASDAQ: IMGO · IEX Real-Time Price · USD
18.36
+1.21 (7.06%)
Aug 12, 2022 4:00 PM EDT - Market closed
7.06%
Market Cap 619.39M
Revenue (ttm) n/a
Net Income (ttm) -51.60M
Shares Out 33.74M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,487
Open 17.19
Previous Close 17.15
Day's Range 16.99 - 18.42
52-Week Range 11.56 - 35.68
Beta n/a
Analysts Buy
Price Target 36.47 (+98.6%)
Earnings Date Aug 18, 2022

About IMGO

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in So... [Read more...]

Industry Biotechnology
IPO Date Jul 16, 2021
Employees 39
Stock Exchange NASDAQ
Ticker Symbol IMGO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for IMGO stock is "Buy." The 12-month stock price forecast is 36.47, which is an increase of 98.64% from the latest price.

Price Target
$36.47
(98.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -

Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for t...

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022

- As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed:

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EH...

- The study completed enrollment with 73 patients in April 2022 -

Imago BioSciences to Host Virtual Investor Event

- Company to host virtual investor event on Saturday, June 11 at 10:30 AM ET following its June 10 th presentation of updated data from Phase 2 studies of bomedemstat for the treatment of Essential Thro...

Imago BioSciences to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for t...

Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates

- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study

Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatm...

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc.  (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for t...

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination wit...

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for th...

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocyt...

Interim Data Update at European Hematology Association (EHA) meeting in June and  Results from Completed Phase 2 Study Expected in Second Half of 2022

Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment ...

Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer

Mr. Arenberg brings over 25 years of experience in the biopharmaceutical industry Mr. Arenberg brings over 25 years of experience in the biopharmaceutical industry

Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment o...

Why Earnings Season Could Be Great for Imago BioSciences (IMGO)

Imago BioSciences (IMGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of...

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at AS...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ASH21--Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ASH21--Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

Imago BioSciences Appoints Laurie Keating to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative...

Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of...

Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of...

Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meetin...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ASH21--Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition

Imago BioSciences Announces Its Addition to the Russell 2000® Index

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO--Imago BioSciences Announces Its Addition to the Russell 2000® Index

Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferati...

Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Ess...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

Imago BioSciences, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferati...